Legal & General Group Plc Acquires New Shares in OPKO Health, Inc. $OPK

Legal & General Group Plc acquired a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 346,787 shares of the biotechnology company’s stock, valued at approximately $520,000.

Several other large investors have also added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company purchased a new position in OPKO Health during the 2nd quarter valued at about $179,000. Algert Global LLC purchased a new stake in shares of OPKO Health in the second quarter worth about $596,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of OPKO Health in the second quarter valued at approximately $618,000. EP Wealth Advisors LLC bought a new position in shares of OPKO Health in the second quarter valued at approximately $45,000. Finally, Ieq Capital LLC purchased a new position in OPKO Health during the second quarter valued at approximately $254,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.59 on Wednesday. OPKO Health, Inc. has a 52-week low of $0.98 and a 52-week high of $1.73. The company has a fifty day moving average of $1.40 and a 200-day moving average of $1.30. The company has a market capitalization of $1.19 billion, a P/E ratio of -17.67 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35.

OPKO Health (NASDAQ:OPK) last released its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The business had revenue of $163.58 million for the quarter, compared to analysts’ expectations of $131.23 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The firm’s revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts predict that OPKO Health, Inc. will post -0.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on OPK shares. HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Finally, Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $1.55.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.